Title Addendum to a systematic review of clinical, laboratory and safety outcomes associated with use of Octaplas in multiple clinical indications

Agency Canadian Agency for Drugs and Technologies in Health (CADTH)
Suite 600, 865 Carling Ave, Ottawa, ON Canada K1S 5S8, Phone: 1-613-226-2553 / Fax: 1-613-226-5392
E-mail: requests@cadth.ca / Web site: http://www.cadth.ca

Reference CADTH Technology Optimal Use Report, May 2011. Available From:
http://www.cadth.ca/media/pdf/SDPlasma_sys-review-addend_e.pdf

Aim

To evaluate the comparative laboratory, clinical and safety outcomes associated with the use of Octaplas (solvent/detergent-treated human plasma) versus frozen plasma (FP) products, and to judge the suitability of Octaplas as an alternative to these products for all clinical indications identified by a comprehensive survey of the literature.

Conclusions and results

Three observational studies were eligible for inclusion in the review. Given the poor quantity and quality of the available evidence, no firm conclusions regarding the effectiveness of Octaplas as a substitute for FP products were possible. Acknowledging these limitations, Octaplas is effective at clinically improving bleeding disorder episodes in patients with acute thrombotic thrombocytopenic purpura (TTP), however, the routine use of Octaplas as initial treatment for TTP cannot be justified based on the included studies; the rates of transfusion- related acute lung injury (TRALI), transfusion-associated infections and other adverse events were lower for Octaplas than for fresh frozen plasma (FFP); no seroconversion was observed in either group for hepatitis (A, B, or C) or human immunodeficiency virus (HIV). Laboratory outcomes were not reported in any of the included studies.

Recommendations

Optimal therapy recommendations for the use of solvent/detergent-treated human plasma based on this and other reports is available from:

http://www.cadth.ca/media/pdf/SDPlasma_rec-report_e.pdf

Methods

A systematic literature search was conducted to identify all recent relevant randomized clinical trials and observational studies evaluating the effectiveness and safety of Octaplas. Two reviewers independently reviewed citations and performed data abstraction for all articles retained for inclusion, according to predefined criteria. Disagreements were settled through consultation with a third party. Indication-specific summaries of all identified research studies are presented in the report, which updates a previous report created in 2007.

Further research/reviews required

Further research comparing Octaplas and standard FP or FFP is needed to evaluate the relative safety and effectiveness of these blood products and to determine the potential impact of Octaplas on health services.

Written by

Jeannine Fraser, Canada